Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW Approves Japan’s 1st SGLT-2 Inhibitor, Boehringer’s Anticancer Drug
January 20, 2014
- Public-Knowledge Based Applications Appropriate for Levonorgestrel, Methylprednisolone Sodium Succinate
January 20, 2014
- Mr Jo of EAD Criticizes Low Price Settlement Rates at Public Hospitals, Warns of Possible Reduction in Medical Fees
January 20, 2014
- PFSB Orders Distribution of Blue Letter on Bayer Yakuhin’s Dysmenorrhea Treatment YAZ Combination Tablets
January 20, 2014
- More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
- Chuikyo Approves General Proposal on Next Medical Fee Revision, Postpones Decision on Divided Dispensing
January 17, 2014
- Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
- PMDA Posts RMPs for Rheumatoid Arthritis Treatment Iguratimod
January 16, 2014
- PFSB Calls for Revision of Package Inserts for Diabetes Drugs Including Lyxumia
January 15, 2014
- PAFSC’s First Committee to Review Second SGLT-2 Inhibitor Dapagliflozin on Jan 24
January 15, 2014
- MHLW Begins Probe into Suspected Data-Tampering of J-ADNI Project
January 15, 2014
- MHLW to Decide Measures by March 2014 to Improve Price Settlement Rates: Ministry Official
January 14, 2014
- Diovan Scandal Could Undermine Confidence in Clinical Studies: Minister Tamura
January 14, 2014
- MHLW Proposes that Medical Institutions Clarify in Invoices that Consumption Tax Is Included in Drug Prices
January 14, 2014
- Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
- MHLW Seeks Criminal Charges against Novartis over Suspected PAL Violations, Diovan Ads Allegedly Misleading
January 10, 2014
- MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
- Guidance on Companion Diagnostics Calls for Inclusion of Biomarker-Negative Subjects in Clinical Studies
January 8, 2014
- MHLW Adds Precaution for Driving in Package Inserts of Donepezil and Other Drugs
January 8, 2014
- MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…